Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

The Original Article was published on 07 January 2021

Correction to: Leukemia 35:20-LEU-1554R

https://doi.org/10.1038/s41375-020-01111-2 published online 07 January 2021

We found an error within Fig. 2B of the manuscript, and unfortunately this was not caught prior to submission and publication. Attached please find the corrected Fig. 2B.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Hagop M. Kantarjian.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kantarjian, H.M., Hughes, T.P., Larson, R.A. et al. Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia (2021). https://doi.org/10.1038/s41375-021-01306-1

Download citation

Search

Quick links